Abstract ID: LBA100 Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC Trial.
讲者：王峰
单位：中山大学肿瘤防治中心
Abstract ID: LBA5 Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer.
专家评述
讲者：袁瑛
单位：浙江大学医学院附属第二医院
Abstract ID: 4013 Postoperative adjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX to improve outcomes of patients with hepatocellular carcinoma with microvascular invasion: A prospective multicenter, phase 3, randomized, controlled clinic
讲者：刘秀峰
单位：东部战区总医院
Abstract ID: 4006 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
讲者：周军
单位：北京大学肿瘤医院
Abstract ID: 4009 Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.
Abstract ID: 4008 Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.
讲者：吴剑挥
Abstract ID: LBA4011 Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.
讲者：李恩孝
单位：西安交通大学医学院第一附属医院
Abstract ID: 8505 Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.
讲者：柳菁菁
单位：吉林省肿瘤医院
